Safety and efficacy of G2-S16 dendrimer as microbicide in healthy human vaginal tissue explants

4Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The absence of an effective treatment and vaccine in HIV-1 pandemic place preventive strategies such as safety and effective microbicide development as a central therapeutic approach to control HIV-1 pandemic nowadays. Results: Studies of cytotoxicity, immune population status, inflammation or tissue damage and mainly prophylactic inhibition of HIV-1 infection in vaginal human explants demonstrate the biosafety and effectivity of G2-S16 dendrimer. Human explants treated with G2-S16 dendrimer or treated and HIV-1 infected do not presented signs of irritation, inflammation, immune activation or T cell populations deregulation. Conclusions: Herein we conclude that G2-S16 dendrimer has demonstrated sufficient efficacy, biosafety, effectivity and behavior in the closest to the real-life condition model represented by the human healthy donor vaginal tissue explants, to raise G2-S16 dendrimer as a promising candidate to clinical trials to develop an effective microbicide against HIV-1 infection. Graphical Abstract: [Figure not available: see fulltext.]

Cite

CITATION STYLE

APA

Rodríguez-Izquierdo, I., Serramía, M. J., Gómez, R., Espinosa, G., Genebat, M., Leal, M., & Muñoz-Fernandez, M. A. (2022). Safety and efficacy of G2-S16 dendrimer as microbicide in healthy human vaginal tissue explants. Journal of Nanobiotechnology, 20(1). https://doi.org/10.1186/s12951-022-01350-8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free